Tất cả tài liệu

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

5 0 0

8 trang

$Single fraction ablative preoperative radiation treatment for early-stage breast cancer: The CRYSTAL study – a phase I/II clinical trial protocol$

Single fraction ablative preoperative radiation treatment for early-stage breast cancer: The CRYSTAL study – a phase I/II clinical trial protocol

3 0 0

12 trang

Real-world treatment patterns for patients 80 years and older with early lung cancer: A nationwide claims study

Real-world treatment patterns for patients 80 years and older with early lung cancer: A nationwide claims study

19 0 0

6 trang

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: A propensity score analysis

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: A propensity score analysis

15 0 0

9 trang

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

8 0 0

15 trang

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: Clinical trial protocol of the MONDRIAN study

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: Clinical trial protocol of the MONDRIAN study

7 0 0

7 trang

SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?

SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?

9 0 0

10 trang